Company

Company image

Company

Company
AI Medical Service Inc.
Business
Development of endoscopic AI (artificial intelligence) to support diagnostic imaging
CEO
Tomohiro Tada
Address
Hareza Tower 11F, 1-18-1 Higashi-ikebukuro, Toshima-ku, Tokyo 170-0013, Japan
Founding
September 1, 2017
Number of employees
(incl. directors, interns)
70 (as of September 2022)
Capital
13.8 billion yen (including reserves)
Acquired External Certification
ISO27001(November 2022)
ISO27701(November 2022)
ISO13485(December 2022)

Office List

Tokyo
Headquarters
Hareza Tower 11F, 1-18-1 Higashi-ikebukuro, Toshima-ku, Tokyo 170-0013, JapanAccess Map
US Branch
 - New York
9th Floor- Chrysler Building, 405 Lexington Ave., New York, NY 10174 USA
Access Map
US Branch
 - Silicon Valley
101 Jefferson Dr. Menlo Park, CA 94025 USA Access Map
Singapore Branch
378 Alexandra Rd, Block 29 Level 1 CIH Co-Working Space, Singapore 159964 Access Map

Access

Four minute walk from the east exit of Ikebukuro Station (JR Line / Tokyo Metro Marunouchi Line, Yurakucho Line, Fuku-Toshin Line / Seibu Ikebukuro Line / Tobu Tojo Line)

History

2017.9
Founding of AI Medical Service, Inc.
2018.1
Developed the world’s first AI for gastric cancer detection using still images
2018.8
Raised funds during a series A round
2019.1
Developed the world’s first AI for esophageal detection using still images
2019.3
Developed the world’s first AI for esophageal detection using videos
2019.10
Raised funds during a series B round
2019.11
Received designated breakthrough device designation from the U.S. Food and Drug Administration (FDA) for our endoscopic system
2020.2
Awarded “EY Innovative Startup 2020”
2020.4
Demonstrated that AI for gastric cancer detection significantly outperforms endoscopists in terms of sensitivity
2020.4
Awarded “Fifth JEITA Venture Award”
2020.8
Relocated our headquarters to Hareza Tower
2020.10
Awarded Grand Prix in the Co-Creation PARK section on “CEATEC AWARD 2020”
2021.1
Demonstrated that endoscopists using AI during review of esophageal cancer videos results in increased sensitivity without decreasing specificity
2021.1
Selected for the “Innovation TOKYO Project” by the Bureau of Industrial and Labor Affairs of the Tokyo Metropolitan Government
2021.1
Designated as "Google for Startups Accelerator Class 3" by Google
2021.4
Finalized a joint research agreement with The National University Hospital, Singapore
2021.5
Launched "gastro AI Online,” a resource for the latest information in endoscopic AI
2021.6
Designated a “Technology Pioneer” by the World Economic Forum
2021.7
Received confirmation that our products comply with the IEC62304 and IEC62366-1 standards for medical devices
2021.8
Applied for regulatory approval for our first product, a device that supports doctors in the classification of gastric cancer
2021.10
Selected as a "J-Startup company" expected to expand business globally
2022.1
Established a US branch in Silicon Valley as a first global base
2022.5
Raised funds during a series C round from Softbank Vision Fund 2 etc.
2022.7
Established a Singapore branch as a second global base
2023.1
Established a US branch in New York as a second US base

AI Medical Service by the numbers

  • Funding Amount (B Yen)

  • Number of employees

  • Number of Countries※Contact with medical institution settled or under negotiation

    HQ/Branch: Tokyo, Sillicon Valley, Singapore

Board Members

  • Tomohiro Tada CEO

    Dr. Tomohiro Tada is the CEO of AI Medical Service Inc., the director of “Tada Tomohiro The Institute of Gastroenterology & Proctology”, and a part-time lecturer at the Department of Surgical Oncology, Graduate School of Medicine at The University of Tokyo.
    Dr. Tada received his M.D. in 1996 and Ph.D. in 2005 from The University of Tokyo School of Medicine. He trained in colorectal surgery at The University of Tokyo Hospital

    Clinical Specialty
    Gastrointestinal Endoscopy

    BOARD CERTIFICATION
    Japan Surgical Society
    Japan Society of Coloproctology
    Japan Gastroenterological Endoscopy Society
    Japan Society of Gastroenterology

  • Yusuke Kato Director & CTO

    Yusuke Kato became a director of AI Medical Service, Inc. in December 2019. He joined the company in 2017 because he was fascinated by the earliest forms of Deep Learning technology. Earlier on, he worked in domestic PC manufacturing company before moving to Fixstars Corporation. Previously, he engaged in the development of video encoders and 3D ray tracers using GPGPU technology.
    He earned a bachelor’s degree in science from the University of Tokyo.

  • Akitoshi Yoshioka Director & CFO

    Akitoshi Yoshioka was appointed to the board in December 2019.
    After working at the audit corporation Tohmatsu (currently Deloitte Touche Tohmatsu, LLC), he joined PKSHA Technology Inc. There, he lead the company to a listing on the TSE Mothers market as director and general manager of the business management division,

  • Hidenari Takahashi Executive Officer &  Division Manager, Product Design, Development and Manufacturing Division 

    Hidenari Takahashi worked for 20 years at medical device manufacturers engaging in product planning, design development, manufacturing, quality assurance, medical affairs.

  • Hidenori Tanaka Executive Officer & Division Manager, Medical Regulatory Management

    Hidenori Tanaka worked for chemical campany and foreign medical device company engaging in product development, manufacturing, evaluation, quality assurance, clinical development, regulatory affairs, delivery, sales, etc.

  • Kenji Yoshida Head of Global Business

    Kenji Yoshida founded a startup in US and expanded its business in US, Japan, Asia, Europe as COO. After returning back to Japan, he initiated global digital health business at Allm Inc..

  • Hiroki Kanai Head of Corporate Planning

    After engaging in management consulting at Mitsubishi Research Institute Inc., Hiroki Kanai joined Rakuten and built several group strategies as office manager of group strategy office.

  • Masaki Naruke
    Head of Business Development

    Throughout his professional career, Masaki Naruke has consistently worked in sales, marketing, and business development in the medical device industry. He has experiences of global marketing and medical device development at Boston Scientific's headquarters in the USA.

  • Takashi Hamada Director, Audit & Supervisory Board Member

    Takashi Hamada is a certified public accountant, appointed as a member of the Audit and Supervisory Committee of the AI Medical Service in 2019. Previously, he was engaged in accounting audits, internal control construction support, IPO support, and financial accounting advisory at a major audit corporation.

  • Jun Yokohama Outside Director

    Graduated from the University of Tokyo, Faculty of Economics, and the University of Chicago Booth School of Business, USA. After working for The Hokkaido Takushoku Bank, Ltd., Partner of Boston Consulting Group, Senior Executive Officer of Fast Retailing Co., Ltd., and President and CEO of Bushu Pharmaceuticals, he became an Executive Officer of Ryohin Keikaku Co., Ltd. He has extensive management experience and has been an outside director of AI Medical Service Inc., since November 2021.

  • Satoshi Fukushima Outside Director

    Satoshi Fukushima was appointed as an outside director of this Company. He joined Globis Capital Partners & Co. in 2014. Prior to joining Globis, he engaged in M&A advisory and financing at the Deutsche Securities Inc and Investment Banking Headquarters. He earned a master’s degree in Economics at the University of Tokyo.

  • Masataka Matsumoto Outside Director

    Masataka Matsumoto joined as the outside director of the AI Medical Service in 2019.
    Previously, he collaborated with other businesses to set up many joint ventures, founding WiL in 2013. He founded PIM Corporation in 1999 and as CEO directed its merger with Yahoo! JAPAN in 2000.

  • Hiroshi Sensaki Outside Director

    Graduated from the University of Tokyo (BA in Economics). He was engaged in principal investments at the Asian Special Situations Group of Goldman Sachs Tokyo. After founding startups and managing companies overseas, he joined SoftBank Group in 2019, and SoftBank Investment Advisers (Vision Fund) in 2022. He was appointed as an outside director of the Company in May 2022.

  • Yusuke Murata Outside Director, Audit & Supervisory Board Member

    Yusuke Murata was appointed as an officer in 2018, and also has been an investor in AIM since its inception. In 2017, he received No. 1 ranking on Forbes Japan's "Ranking of the Most Influential Venture Investors in Japan.” He established Incubate Fund in 2010.

  • Hidekazu Suzuki Outside Director, Audit & Supervisory Board Member

    After serving as an outside director and corporate auditor of several companies, Hidekazu Suzuki became a director and member of AI Medical Service’s audit and supervisory committee in 2018. He was president of Arbeit-Times Co., Ltd.

Contact

Feel free to contact us using the form below regarding joint research,
media coverage, business partnerships, or related opportunities.